JP2023542092A5 - - Google Patents
Info
- Publication number
- JP2023542092A5 JP2023542092A5 JP2023515682A JP2023515682A JP2023542092A5 JP 2023542092 A5 JP2023542092 A5 JP 2023542092A5 JP 2023515682 A JP2023515682 A JP 2023515682A JP 2023515682 A JP2023515682 A JP 2023515682A JP 2023542092 A5 JP2023542092 A5 JP 2023542092A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- administered
- bispecific antibody
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063076818P | 2020-09-10 | 2020-09-10 | |
| US63/076,818 | 2020-09-10 | ||
| US202163164255P | 2021-03-22 | 2021-03-22 | |
| US63/164,255 | 2021-03-22 | ||
| PCT/EP2021/075022 WO2022053658A1 (en) | 2020-09-10 | 2021-09-10 | Bispecific antibody against cd3 and cd20 in combination therapy for treating diffuse large b-cell lymphoma |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023542092A JP2023542092A (ja) | 2023-10-05 |
| JP2023542092A5 true JP2023542092A5 (cg-RX-API-DMAC7.html) | 2024-09-18 |
Family
ID=77914295
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023515682A Pending JP2023542092A (ja) | 2020-09-10 | 2021-09-10 | びまん性大細胞型b細胞リンパ腫を治療するための併用療法におけるcd3及びcd20に対する二重特異性抗体 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US20230312759A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4210745A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2023542092A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20230066392A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2021342343A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112023004319A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3192256A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL301100A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2023002541A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022053658A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20230008775A (ko) | 2020-05-08 | 2023-01-16 | 젠맵 에이/에스 | Cd3 및 cd20에 대한 이중특이적 항체 |
| CN116437956A (zh) | 2020-09-10 | 2023-07-14 | 健玛保 | 用于治疗慢性淋巴细胞白血病的针对cd3和cd20的双特异性抗体 |
| JP2023542290A (ja) | 2020-09-10 | 2023-10-06 | ジェンマブ エー/エス | 濾胞性リンパ腫を治療するための併用療法におけるcd3及びcd20に対する二重特異性抗体 |
| WO2022053654A1 (en) | 2020-09-10 | 2022-03-17 | Genmab A/S | Bispecific antibody against cd3 and cd20 in combination therapy for treating diffuse large b-cell lymphoma |
| WO2022053657A1 (en) | 2020-09-10 | 2022-03-17 | Genmab A/S | Bispecific antibody against cd3 and cd20 in combination therapy for treating diffuse large b-cell lymphoma |
| IL301086A (en) | 2020-09-10 | 2023-05-01 | Genmab As | Bispecific antibody against cd3 and cd20 in combination therapy for treating follicular lymphoma |
| WO2024236031A1 (en) | 2023-05-15 | 2024-11-21 | Genmab A/S | Highly purified epcoritamab compositions |
| TW202602494A (zh) * | 2024-04-12 | 2026-01-16 | 美商建南德克公司 | 格菲妥單抗與化學療法之組合治療 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0590058B1 (en) | 1991-06-14 | 2003-11-26 | Genentech, Inc. | HUMANIZED Heregulin ANTIBODy |
| GB9203459D0 (en) | 1992-02-19 | 1992-04-08 | Scotgen Ltd | Antibodies with germ-line variable regions |
| EP0979281B1 (en) | 1997-05-02 | 2005-07-20 | Genentech, Inc. | A method for making multispecific antibodies having heteromultimeric and common components |
| KR100944575B1 (ko) | 2002-10-17 | 2010-02-25 | 젠맵 에이/에스 | Cd20에 대한 인간 모노클로날 항체 |
| KR101374454B1 (ko) | 2005-03-31 | 2014-03-17 | 추가이 세이야쿠 가부시키가이샤 | 회합제어에 의한 폴리펩티드 제조방법 |
| KR101866623B1 (ko) | 2005-11-28 | 2018-07-04 | 젠맵 에이/에스 | 재조합 1가 항체 및 그의 제조 방법 |
| EP3663318A1 (en) | 2008-01-07 | 2020-06-10 | Amgen Inc. | Method for making antibody fc-heterodimeric molecules using electrostatic steering effects |
| US9067986B2 (en) | 2009-04-27 | 2015-06-30 | Oncomed Pharmaceuticals, Inc. | Method for making heteromultimeric molecules |
| TWI426920B (zh) | 2010-03-26 | 2014-02-21 | Hoffmann La Roche | 雙專一性、雙價抗-vegf/抗-ang-2抗體 |
| PT2560993T (pt) | 2010-04-20 | 2024-09-16 | Genmab As | Proteínas contendo anticorpo heterodimérico fc e métodos para a produção das mesmas |
| IN2014CN03887A (cg-RX-API-DMAC7.html) | 2011-10-27 | 2015-10-16 | Genmab As | |
| KR102813816B1 (ko) | 2013-07-05 | 2025-05-29 | 젠맵 에이/에스 | 인간화 또는 키메라 cd3 항체 |
| CN107660214B (zh) * | 2015-01-08 | 2022-02-08 | 根马布股份公司 | 针对cd3和cd20的双特异性抗体 |
| EP3541843A1 (en) * | 2016-11-15 | 2019-09-25 | Genentech, Inc. | Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies |
| BR112020015052A2 (pt) | 2018-02-09 | 2020-12-08 | Genmab A/S | Composição farmacêutica, uso da composição farmacêutica, métodos para tratar câncer em um sujeito, para preparar uma composição farmacêutica e para preparar uma forma de dosagem unitária, forma de dosagem unitária, recipiente, e, kit-de-partes |
-
2021
- 2021-09-10 BR BR112023004319A patent/BR112023004319A2/pt unknown
- 2021-09-10 KR KR1020237011606A patent/KR20230066392A/ko active Pending
- 2021-09-10 IL IL301100A patent/IL301100A/en unknown
- 2021-09-10 US US18/025,208 patent/US20230312759A1/en active Pending
- 2021-09-10 WO PCT/EP2021/075022 patent/WO2022053658A1/en not_active Ceased
- 2021-09-10 MX MX2023002541A patent/MX2023002541A/es unknown
- 2021-09-10 JP JP2023515682A patent/JP2023542092A/ja active Pending
- 2021-09-10 CA CA3192256A patent/CA3192256A1/en active Pending
- 2021-09-10 AU AU2021342343A patent/AU2021342343A1/en active Pending
- 2021-09-10 EP EP21777656.6A patent/EP4210745A1/en active Pending
- 2021-12-22 US US17/559,965 patent/US20220112309A1/en not_active Abandoned